glp-1 drug companies Market Industry Trends and Global Forecasts 2024-2035: Over 150 GLP-1 Candidates in Development for Multiple Indications, Type 2 Diabetes and Obesity Drive GLP-1 Drug Development Boom GLP-1 Receptor Agonist Companies and

Description

Piao L, Zhao G, Zhu E, Inoue A, Shibata R, Lei Y, Hu L, Yu C, Yang G, Wu H

Cost per member per month (PMPM) increased exponentially from $4.34 in 2022 to $19.19 in Q1-Q3 2024

In a motion to dismiss the lawsuit last year, lawyers for Mochi Health called the complaint part of a nationwide campaign to bolster Lillys profits by dictating patient care through the elimination of compounded drugs as a treatment option for weight management. The lawsuit is ongoing

10.4239/wjd.v10.i5.291 148 ReadP

In addition, a large-scale clinical study demonstrated that GLP-1 analogues could reduce the mortality of patients with prostate cancer and diabetes (19)